How high should an ACE inhibitor or angiotensin receptor blocker be dosed in patients with diabetic nephropathy?-Reference-Cited by-同舟云学术

How high should an ACE inhibitor or angiotensin receptor blocker be dosed in patients with diabetic nephropathy?

Published:2003-10 Issue:5 Volume:5 Page:418-425
ISSN:1522-6417
Container-title:Current Hypertension Reports
language:en
Short-container-title:Current Science Inc

Author:

Weinberg Marc S.,Kaperonis Nicholas,Bakris George L.

Publisher

Springer Science and Business Media LLC

Subject

Internal Medicine

Link

http://link.springer.com/content/pdf/10.1007/s11906-003-0088-8.pdf

Reference63 articles.

1. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 2002, 39:S1–S246.

2. Arauz-Pacheco C, Parrott MA, Raskin P: Treatment of hypertension in adults with diabetes. Diabetes Care 2003, 26:S80-S82.

3. Molitch ME, DeFronzo RA, Franz MJ, et al.: Diabetic nephropathy. Diabetes Care 2003, 26:S94-S98.

4. Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851–886. The first of the two large studies that accounted for an ARB recommendation in type 2 diabetes. In this study the superiority of irbesartan was shown compared with amlodipine.

5. Brenner BM, Cooper ME, de Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type diabetes and nephropathy. N Engl J Med 2001, 345:861–869. This study clearly disclosed the significant effect of the ARB (losartan) on preventing the progression to hard endpoints.

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Can patiromer allow for intensified renin–angiotensin–aldosterone system blockade with losartan and spironolactone leading to decreased albuminuria in patients with chronic kidney disease, albuminuria and hyperkalaemia? An open-label randomised controlled trial: MorphCKD;BMJ Open;2022-02

2. Novel effective drugs for diabetic kidney disease? or not?;Expert Opinion on Emerging Drugs;2014-11-07

3. Diabetes and Health Care;Diabetes Mellitus and Human Health Care;2014-01-15

4. Diabetic nephropathy;Diabetology & Metabolic Syndrome;2009-09-21

5. Response to ‘Telmisartan is more effective than losartan in reducing proteinuria’;Kidney International;2009-01